CGT Development Is Booming, But Manufacturing Workforce Must Keep Up
Due to the unprecedented growth in the development of cell and gene therapies over the past decade, there is now high demand for certain workforce roles, especially in highly specialized areas and entry-level manufacturing positions.
You may also be interested in...
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
Ongoing debate emanates from industry players around the most efficient design of the manufacturing process for cell and gene therapies. The arguments surrounding outsourcing, centralizing, and standardizing processes will no doubt continue through into the near future.
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.